相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J. Giffin et al.
CLINICAL CANCER RESEARCH (2021)
Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?
Marco Volante et al.
ENDOCRINE PATHOLOGY (2021)
Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery
Li Liu et al.
HUMAN PATHOLOGY (2021)
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments
Dipesh Uprety et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
DLL3expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonaryLCNEC
Hiroyuki Ogawa et al.
THORACIC CANCER (2020)
International real-world study of DLL3 expression in patients with small cell lung cancer
Federico Rojo et al.
LUNG CANCER (2020)
The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy
Salomon Tendler et al.
PLOS ONE (2020)
DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
Megumi Furuta et al.
CANCER SCIENCE (2019)
Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics
Richard S. P. Huang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures
Luka Brcic et al.
DIAGNOSTIC PATHOLOGY (2019)
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)
Megumi Furuta et al.
ONCOLOGIST (2019)
DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer
Jianling Huang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
DLL3: an emerging target in small cell lung cancer
Dwight H. Owen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy
Kentaro Matsuo et al.
CANCER SCIENCE (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors
Hao Xie et al.
LUNG CANCER (2019)
Current Diagnosis and Management of Small-Cell Lung Cancer
Shuhang Wang et al.
MAYO CLINIC PROCEEDINGS (2019)
Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids
N. Alcala et al.
NATURE COMMUNICATIONS (2019)
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target
Vadim S. Koshkin et al.
CLINICAL CANCER RESEARCH (2019)
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile
B. C. M. Hermans et al.
LUNG CANCER (2019)
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
Kentaro Tanaka et al.
LUNG CANCER (2018)
Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors
Julie George et al.
NATURE COMMUNICATIONS (2018)
Immunotherapy of lung cancer Preface
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC DISEASE (2018)
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate
Bilal H. Lashari et al.
DRUGS IN R&D (2018)
Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer A retrospective study
Juan Wang et al.
MEDICINE (2018)
The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database
Pier Luigi Filosso et al.
JOURNAL OF THORACIC DISEASE (2018)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Management of pulmonary neuroendocrine tumors
Robert A. Ramirez et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2017)
Distinctive pathological and clinical features of lung carcinoids with high proliferation index
Caterina Marchio et al.
VIRCHOWS ARCHIV (2017)
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies
Robert J. Cardnell et al.
ONCOTARGET (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Notch Signaling Components Diverging Prognostic Indicators in Lung Adenocarcinoma
Zhi-Yan Liu et al.
MEDICINE (2016)
Notch signalling in context
Sarah J. Bray
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Notch Signaling in Neuroendocrine Tumors
Judy S. Crabtree et al.
FRONTIERS IN ONCOLOGY (2016)
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
M. E. Caplin et al.
ANNALS OF ONCOLOGY (2015)
Pulmonary Large-Cell Neuroendocrine Carcinoma From Epidemiology to Therapy
Morena Fasano et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis
Gavin Chapman et al.
HUMAN MOLECULAR GENETICS (2011)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
